Phthalates, Gestational Diabetes, and Markers of Type 2 Diabetes Risk in Women
邻苯二甲酸盐、妊娠期糖尿病和女性 2 型糖尿病风险标志物
基本信息
- 批准号:10058771
- 负责人:
- 金额:$ 40.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-04-02 至 2022-11-30
- 项目状态:已结题
- 来源:
- 关键词:AwarenessBindingBiological MarkersBlood GlucoseBody SizeCase StudyChemical ExposureChemicalsCohort StudiesCosmeticsCross-Sectional StudiesDataDevelopmentDiagnosisDietEndocrine DisruptorsEnvironmentEnvironmental Risk FactorEpidemicEpidemiologyExposure toFastingFirst Pregnancy TrimesterFollow-Up StudiesFood PackagingFutureGenesGestational DiabetesGlucoseGlycosylated hemoglobin AHormonesHourHumanInsulinLife StyleLiteratureLongitudinal StudiesMeasuresNested Case-Control StudyNon-Insulin-Dependent Diabetes MellitusNuclear ReceptorsOGTTPPAR alphaPathway interactionsPlasticsPopulationPostpartum PeriodPostpartum WomenPregnancyPrevalenceRecording of previous eventsResearchResearch DesignRiskRisk FactorsRoleSecond Pregnancy TrimesterSerumSomatotypeSuggestionTargeted ResearchTestingTimeUnited NationsWeightWomanWorld Health Organizationadverse pregnancy outcomebasecohortconsumer productdesigndiabetes riskepidemiologic datagestational weight gainglucose metabolismhigh riskimpaired glucose tolerancelifestyle factorsmodifiable riskphthalatesprepregnancyprogramspublic health relevancereceptorrecruitsecondary analysisstudy populationurinary
项目摘要
DESCRIPTION (provided by applicant): Over the past several decades, the prevalence of gestational diabetes (GDM) has increased 3-fold, with implications for the growing type 2 diabetes (T2DM) epidemic among women with a history of this condition. An increasing body of literature suggests that phthalates, an endocrine disrupting chemical, are associated with increased T2DM risk in non-pregnant women. These chemicals are used in plastics, food packaging, cosmetics, and other consumer products. Phthalates bind to the nuclear receptors, peroxisome proliferator activated receptors (PPAR) alpha and gamma, which may modulate target genes that regulate glucose metabolism. While phthalates have been found to be associated with T2DM risk among non-pregnant women, it remains unclear whether these chemicals are associated with GDM risk. Preliminary data from our research suggest associations between urinary levels of mono-benzyl (MBzP) and mono-(3-carboxypropyl) (MCPP) phthalates and pregnancy-related risk factors of GDM, such as increased pre-pregnancy weight, excessive gestational weight gain, and elevated blood glucose levels during pregnancy among a subset of women (n=350) participating in an ongoing pregnancy cohort study of 4,000 women. Yet, no studies have assessed the association between phthalate levels and GDM risk. In addition, GDM is known to substantially increase future development of T2DM, with over 50% of women with a history of GDM going on to develop T2DM. This increased risk can be seen as early as 6-weeks postpartum, with women with higher fasting and 2-hour blood glucose levels being at substantially higher risk of developing T2DM in the future. However, no studies have evaluated the association between phthalate levels during and after pregnancy to determine whether these chemicals contribute to an increased risk of sustained glucose dysregulation after pregnancy. To this end, we propose conducting a nested case-control study in an established pregnancy cohort to assess the association between 1st and 2nd trimester urinary metabolite levels of mono-benzyl phthalate and mono-(3-carboxypropyl) phthalate and GDM risk, as well as biomarkers associated with GDM risk (i.e. blood glucose levels) among 560 women. We will also conduct a post-pregnancy follow-up study in 866 newly recruited women, including those with GDM, impaired glucose tolerance, and normal glycemia, to evaluate the association of higher pregnancy and post-pregnancy levels of MBzP and MCPP and post-pregnancy glucose, insulin, hemoglobin A1c, and HOMA-IR levels at 6-weeks postpartum as measures of sustained glucose dysregulation after pregnancy. By evaluating the role of phthalate levels and diabetes risk at two sensitive time points-pregnancy and the postpartum, this research will give better understanding for the role of these highly-prevalent endocrine disrupting chemicals on GDM and future T2DM risk, with implications for identifying modifiable risk factors.
描述(由适用提供):在过去的几十年中,妊娠糖尿病(GDM)的患病率增加了3倍,对具有这种病史的妇女的2型型糖尿病(T2DM)含义。越来越多的文献表明,邻苯二甲酸盐是一种破坏化学物质的邻苯二甲酸盐与非怀孕妇女的T2DM风险增加有关。这些化学物质用于塑料,食品包装,化妆品和其他消费产品。邻苯二甲酸酯与核受体,过氧化物组增殖者活化受体(PPAR)α和伽马结合,它们可能调节调节葡萄糖代谢的靶基因。虽然已经发现邻苯二甲酸酯与非孕妇的T2DM风险有关,但尚不清楚这些化学物质是否与GDM风险相关。来自我们研究的初步数据表明,单苯苯基(MBZP)和单(3-羧基丙基)(MCPP)(MCPP)邻苯二甲酸酯与GDM的妊娠危险因素之间的关联,例如孕妇体重的增加,超过妊娠妇女的孕妇(N = 350)在孕妇中的较高症状(等级)(n = 350)的研究(例如,孕妇的升高水平) 4,000名妇女。然而,尚无研究评估邻苯二甲酸酯水平与GDM风险之间的关联。此外,众所周知,GDM大大增加了T2DM的未来发展,其中超过50%的具有GDM病史的女性正在开发T2DM。这种增加的风险早在产后6周就可以看到,而空腹和2小时的血糖水平较高的女性将来患有T2DM的风险更高。但是,尚无研究评估怀孕期间和之后邻苯二甲酸酯水平之间的关联,以确定这些化学物质是否有助于妊娠后持续葡萄糖失调的风险增加。为此,我们建议在既定的妊娠队列中进行一项嵌套的病例对照研究,以评估单个苯二苯二甲酸酯邻苯二甲酸酯和单(3-羧基丙酰基)苯甲酸酯和GDM风险和GDM风险的1-和第二个三生代谢物水平之间的关联。 We will also conduct a post-pregnancy follow-up study in 866 newly recruited women, including those with GDM, impaired glucose tolerance, and normal glycemia, to evaluate the association of higher pregnancy and post-pregnancy levels of MBzP and MCPP and post-pregnancy glucose, insulin, hemoglobin A1c, and HOMA-IR levels at 6-weeks postpartum as measures of sustained怀孕后葡萄糖失调。通过评估邻苯二甲酸酯水平和糖尿病风险在两个敏感的时间点孕和产后的作用,这项研究将更好地理解这些高度耐受的内分泌内分泌中断化学物质对GDM和未来T2DM风险的作用,并具有识别可修改风险因素的影响。
项目成果
期刊论文数量(9)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
A prospective study of early pregnancy essential metal(loid)s and glucose levels late in the second trimester.
- DOI:10.1210/jc.2019-00109
- 发表时间:2019-10
- 期刊:
- 影响因子:0
- 作者:Yinnan Zheng;Cuilin Zhang;M. Weisskopf;Paige L. Williams;P. Parsons;C. Palmer;G. B. Buck Louis;T. James-Todd
- 通讯作者:Yinnan Zheng;Cuilin Zhang;M. Weisskopf;Paige L. Williams;P. Parsons;C. Palmer;G. B. Buck Louis;T. James-Todd
Time-specific placental growth factor (PlGF) across pregnancy and infant birth weight in women with preexisting diabetes.
患有糖尿病的女性在怀孕和婴儿出生体重期间的时间特异性胎盘生长因子(PlGF)。
- DOI:10.3109/10641955.2016.1172085
- 发表时间:2016
- 期刊:
- 影响因子:1.5
- 作者:James-Todd,Tamarra;Cohen,Allison;Wenger,Julia;Brown,Florence
- 通讯作者:Brown,Florence
Paternal bias: The impact of not accounting for paternal confounders in reproductive epidemiological studies.
- DOI:10.1016/j.ajog.2019.08.005
- 发表时间:2020-01
- 期刊:
- 影响因子:9.8
- 作者:Bellavia A;Mitro SD;Hauser R;James-Todd T
- 通讯作者:James-Todd T
Multiple mediators approach to study environmental chemicals as determinants of health disparities.
- DOI:10.1097/ee9.0000000000000015
- 发表时间:2018-06-01
- 期刊:
- 影响因子:0
- 作者:Bellavia, Andrea;Zota, Ami R;James-Todd, Tamarra
- 通讯作者:James-Todd, Tamarra
Racial/ethnic disparities in environmental endocrine disrupting chemicals and women's reproductive health outcomes: epidemiological examples across the life course.
- DOI:10.1007/s40471-016-0073-9
- 发表时间:2016-06
- 期刊:
- 影响因子:3.3
- 作者:James-Todd TM;Chiu YH;Zota AR
- 通讯作者:Zota AR
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tamarra M James-Todd其他文献
Tamarra M James-Todd的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Tamarra M James-Todd', 18)}}的其他基金
Pregnancy and postpartum as vulnerable exposure windows: phthalates and maternal cardiometabolic health
怀孕和产后是脆弱的暴露窗口:邻苯二甲酸盐和孕产妇心脏代谢健康
- 批准号:
10476635 - 财政年份:2021
- 资助金额:
$ 40.66万 - 项目类别:
Per- and Polyfluoroalkyl substances mixtures and maternal cardiovascular disease risk across the reproductive life course
全氟烷基和多氟烷基物质混合物与整个生殖生命过程中孕产妇心血管疾病的风险
- 批准号:
10267734 - 财政年份:2020
- 资助金额:
$ 40.66万 - 项目类别:
Per- and Polyfluoroalkyl substances mixtures and maternal cardiovascular disease risk across the reproductive life course
全氟烷基和多氟烷基物质混合物与整个生殖生命过程中孕产妇心血管疾病的风险
- 批准号:
10653011 - 财政年份:2020
- 资助金额:
$ 40.66万 - 项目类别:
Per- and Polyfluoroalkyl substances mixtures and maternal cardiovascular disease risk across the reproductive life course
全氟烷基和多氟烷基物质混合物与整个生殖生命过程中孕产妇心血管疾病的风险
- 批准号:
10438890 - 财政年份:2020
- 资助金额:
$ 40.66万 - 项目类别:
Phthalates, Gestational Diabetes, and Markers of Type 2 Diabetes Risk in Women
邻苯二甲酸盐、妊娠期糖尿病和女性 2 型糖尿病风险标志物
- 批准号:
9188078 - 财政年份:2016
- 资助金额:
$ 40.66万 - 项目类别:
Phthalates, Gestational Diabetes, and Markers of Type 2 Diabetes Risk in Women
邻苯二甲酸盐、妊娠期糖尿病和女性 2 型糖尿病风险标志物
- 批准号:
9606480 - 财政年份:2016
- 资助金额:
$ 40.66万 - 项目类别:
相似国自然基金
基于靶向代谢组学结合肽指纹谱非标记药物靶标分析新方法的紫草素抑制白念珠菌生物被膜作用机制研究
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于靶向代谢组学结合肽指纹谱非标记药物靶标分析新方法的紫草素抑制白念珠菌生物被膜作用机制研究
- 批准号:82104127
- 批准年份:2021
- 资助金额:24.00 万元
- 项目类别:青年科学基金项目
维生素D结合蛋白介导小胶质细胞和神经元交互作用参与抑郁发生分子和环路机制及其诊疗生物学标记物研究
- 批准号:82130042
- 批准年份:2021
- 资助金额:291 万元
- 项目类别:重点项目
15N标记麻痹性贝类毒素在牡蛎中转化及壳聚糖衍生物脱毒机制
- 批准号:31772089
- 批准年份:2017
- 资助金额:60.0 万元
- 项目类别:面上项目
新型非标记位点可控型功能DNA荧光传感器的开发及在环境检测和生物分析中的应用
- 批准号:21775084
- 批准年份:2017
- 资助金额:65.0 万元
- 项目类别:面上项目
相似海外基金
The cardiovascular consequences of sleep apnea plus COPD (Overlap syndrome)
睡眠呼吸暂停加慢性阻塞性肺病(重叠综合征)对心血管的影响
- 批准号:
10733384 - 财政年份:2023
- 资助金额:
$ 40.66万 - 项目类别:
Inequities in Childhood Life-Course Lead Exposure and Academic and Neurobehavioral Outcomes (I-CLEAN)
童年生命历程铅暴露以及学业和神经行为结果的不平等(I-CLEAN)
- 批准号:
10660566 - 财政年份:2023
- 资助金额:
$ 40.66万 - 项目类别:
Role of IgA-biome in intestinal dysbiosis and brain changes in Alzheimer's disease
IgA 生物组在阿尔茨海默病肠道菌群失调和大脑变化中的作用
- 批准号:
10667011 - 财政年份:2023
- 资助金额:
$ 40.66万 - 项目类别:
Preparation of sequencing libraries for multi-analyte analysis of small RNAs
制备用于小 RNA 多分析物分析的测序文库
- 批准号:
10759916 - 财政年份:2023
- 资助金额:
$ 40.66万 - 项目类别:
Novel mechanism for sex differences in hearing loss
听力损失性别差异的新机制
- 批准号:
10659402 - 财政年份:2023
- 资助金额:
$ 40.66万 - 项目类别: